Ababax
Ababax is a company focused on developing digital drug delivery products aimed at treating conditions such as depression, anxiety, myopia, and cognitive decline. It utilizes non-invasive brain stimulation technologies that can be accessed through standard consumer devices like smartphones. By integrating findings from neuroscience, machine learning, and psychology, Ababax creates solutions that modify communication between neuron populations and brain regions, thereby enhancing mental health and cognitive function. The company's innovative approach positions it at the intersection of technology and healthcare, seeking to improve well-being through scientifically-driven methods.
Dopavision GmbH, founded in 2017 and based in Berlin, Germany, focuses on developing a digital therapeutic for myopia, or shortsightedness, a common visual condition affecting around one in three individuals globally. The company aims to create a clinically validated therapy to slow the progression of myopia in children and adolescents. Its innovative technology employs light stimulation targeting specific photosensitive cells in the retina, which modulates dopamine levels—a neurotransmitter that plays a crucial role in eye growth regulation. This digital therapeutic can be seamlessly integrated with smartphone use, making it an accessible solution for health professionals treating myopia. Dopavision is also supported by the German government through the "Industrie-in-Klinik" program, receiving €1.4 million over three years to advance its research and development efforts.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.